Side-by-side comparison of AI visibility scores, market position, and capabilities
AI-powered long-acting injectable drug formulation platform cutting development from 5 years to 2; $12M Series A with Eli Lilly investment competing in microsphere CDMO development.
Persist AI is a pharmaceutical formulation company operating an AI-powered drug formulation platform with robotic cloud lab capabilities — specializing in the development of long-acting injectable (LAI) microsphere formulations that can deliver drug release over weeks or months (up to one year), addressing the adherence challenges of daily oral medications for chronic conditions including mental health, addiction, HIV, contraception, and oncology. Founded in 2022 and backed by $16 million including a $12 million Series A led by Spero Ventures with participation from Eli Lilly, Persist AI accelerates drug development timelines by approximately 50%, reducing typical 5-year formulation development to 2 years.\n\nPersist AI's platform combines AI-driven formulation design (predicting which polymer/drug/process combinations will achieve target release profiles) with robotic laboratory execution (automated synthesis and testing of formulation candidates) and analytics that identify optimal formulations faster than traditional trial-and-error approaches. The microsphere technology encapsulates drug molecules in biodegradable polymer spheres that gradually release the drug as the polymer degrades — a proven technology (Risperdal Consta, Lupron Depot) but one that takes years to develop with traditional methods. Eli Lilly's participation as an investor signals pharma validation of the platform approach.\n\nIn 2025, Persist AI competes in the drug formulation and CDMO (contract development and manufacturing) market with EVO Pharma, Polymeropoulos (a long-acting injectable specialist), and larger CDMOs including Lonza and Catalent for LAI microsphere development services. The long-acting injectable market is growing as mental health conditions (schizophrenia, bipolar) see improved outcomes with LAI antipsychotics that eliminate the adherence problem — patients who receive monthly or quarterly injections have significantly better medication compliance than those taking daily pills. The 2025 strategy focuses on growing pharma company partnerships for LAI development projects, advancing internal pipeline candidates toward clinical trials, and building the manufacturing scale-up capabilities needed for commercial supply.
Open-source observability leader with $6B valuation; Grafana dashboards plus Loki/Tempo/Mimir stack serving millions of installations as Datadog alternative with community-driven adoption.
Grafana Labs is the company behind Grafana — the world's most widely used open-source observability and data visualization platform — providing the Grafana Cloud managed service, Grafana Enterprise, and a suite of open-source tools including Loki (log aggregation), Tempo (distributed tracing), and Mimir (long-term Prometheus metrics storage). Founded in 2019 by Raj Dutt, Torkel Ödegaard, and Tom Wilkie (the creators of the original Grafana open-source project) in New York, Grafana Labs has raised over $600 million at a $6 billion valuation.\n\nGrafana's open-source project — downloadable and self-hostable for free — has driven extraordinary community adoption: millions of Grafana installations globally power engineering, IoT, and business dashboards at organizations from startups to large enterprises. Grafana's plugin ecosystem connects to 200+ data sources (Prometheus, InfluxDB, Elasticsearch, AWS CloudWatch, databases), making it the universal observability visualization layer. Grafana Cloud packages the open-source tools into a fully managed SaaS offering with unlimited metrics, logs, traces, and dashboards.\n\nIn 2025, Grafana Labs competes in the observability platform market against Datadog, New Relic, Dynatrace, and the ELK/OpenSearch stack for enterprise monitoring and observability. Grafana's open-source-first model creates a moat through developer community and ecosystem — engineers who build personal dashboards on Grafana become advocates for Grafana Cloud at their employers. The company's OpenTelemetry alignment and multi-source data philosophy ("query any data, anywhere") differentiates it from Datadog's monolithic agent model. The 2025 strategy focuses on growing Grafana Cloud enterprise adoption, advancing AI-powered Sift (automatic anomaly investigation), and expanding the Grafana IRM (incident response management) product.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.